60%+ returns in 2025: Here’s how AI-powered stock investing has changed the game
Director Janet Dillione of CorMedix Inc. (NASDAQ:CRMD) sold 26,343 shares of common stock on November 24, 2025, for approximately $261,585. The shares were sold at a weighted average price of $9.93, with individual sales prices ranging from $9.72 to $10.00. The transaction occurred with CRMD trading near $9.65, approximately 45% below its 52-week high of $17.43, despite the company’s strong financial health score rated as "GREAT" by InvestingPro.
On the same day, Dillione also exercised options to acquire a total of 26,343 shares of CorMedix common stock at prices ranging from $2.85 to $4.43, for a total value of $95947. These transactions involved the exercise of stock options at strike prices of $2.85 (8,000 shares), $4.03 (7,790 shares), $4.43 (4,876 shares) and $3.55 (5,677 shares). The insider activity comes as CorMedix, with a market capitalization of approximately $758 million, trades at an attractive P/E ratio of 4.26 and has posted impressive revenue growth.
Following these transactions, Dillione directly owns 48,473 shares of CorMedix Inc . InvestingPro analysis indicates the company is currently undervalued and has been profitable over the last twelve months, with analysts expecting continued growth. For deeper insights into CRMD’s financial health and growth prospects, InvestingPro offers a comprehensive Research Report with 10+ additional ProTips and expert analysis on this promising healthcare stock.
In other recent news, CorMedix Inc. reported an impressive financial performance for the third quarter of 2025, significantly surpassing market expectations. The company achieved earnings per share of $1.26, which was much higher than the anticipated $0.43, representing a surprise of 193.02%. Additionally, CorMedix’s revenue reached $104.3 million, outperforming the forecasted $65.9 million. These results reflect strong investor confidence in the company’s financial health. There were no reports of mergers or acquisitions in this period. Analysts’ upgrades or downgrades were not mentioned in the recent developments. These financial achievements highlight the company’s robust performance in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.